Health News

Depression, especially in urban areas, is on the rise, now more than ever. Mental health outcomes are influenced by, among other things, the type of environment where one lives.

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure.

Wireless communication directly between brains is one step closer to reality thanks to $8 million in Department of Defense follow-up funding for Rice University neuroengineers.

The American Heart Association, the leading global voluntary health organization dedicated to fighting heart disease and stroke, is making an unprecedented series of investments focused on enhancing its historic commitment to addressing the social determinants of health and the barriers to achieving health equity for all communities – urban, suburban and rural.

In a recent review published in the Journal of Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Luigi Santacroce and Francesco Inchingolo et al. address the many factors such as dysbiosis (imbalance in the microbiota) that could influence the SARS-CoV-2 infection course.

Children of mothers experiencing depressive symptoms are more at risk, as adolescents, of experiencing suicidal thoughts and attempting suicide.

Researchers studying the effect of convalescent sera and monoclonal antibodies from recovered patients found the UK and South African SARS-CoV-2 variants are more resistant to neutralization compared to the wild-type virus.

Study conducted by researchers from the GIGA CRC In vivo Imaging laboratory at ULiège demonstrates, for the first time in humans, how the first deposits of tau proteins in the brainstem are associated with neurophysiological processes specific to the early stages of Alzheimer’s disease development.

The Nagoya University Institute of Transformative Bio-Molecules research team of Designated Associate Professor Tsuyoshi Hirota, Postdoctoral Fellow Simon Miller, Professor Kenichiro Itami and graduate student Tsuyoshi Oshima (Research Fellowship for Young Scientists, JSPS), in collaboration with the group of Professor Ben Feringa and Postdoctoral Fellow Dušan Kolarski of Groningen University in the Netherlands, have achieved a world first: fully reversible manipulation of the period of the circadian clock using light, by exchanging part of a compound with a light-activated switch.

“Transparency is crucial for informed public debate, democratic accountability, and public trust,” said Olivier Hoedeman of Corporate Europe Observatory.

Merck will stop developing both formulations of the Covid-19 vaccines the company was working on, citing inadequate immune responses to the shots.

Moderna is studying whether booster doses could be necessary after finding its Covid-19 vaccine was less effective against a coronavirus variant that was first identified in South Africa.

As Merck bows out of the race to develop Covid-19 vaccines, it plans to continue developing treatments for the disease.

A new administration and Congress getting to work offers an opportunity to reverse the uninsured trend line. This can be done quickly and without sweeping change to the health system.…

Covid-19 vaccine basics: Why the rollout is so slow, when it will pick up, and who can get it.

The analysis suggests that political leanings have helped suppress the true scale of Covid-19 deaths. In cases where the deceased didn’t have a Covid-19 test, a coroner or medical examiner…

Deborah Birx said she waited to give an interview about her experiences as the coordinator of the White House Coronavirus Task Force until after President Joe Biden’s inauguration.

Aurinia Pharmaceuticals won approval to market a new medicine for patients with lupus nephritis, a serious autoimmune kidney disease.

As a weary and uncertain America faces the likelihood of needing continual rollout of new coronavirus treatments in the years to come, the stakes for President Biden’s choice for FDA…